Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination With Fulvestrant in Patients With AKT1(E17K)-Mutant, ER-Positive Metastatic Breast Cancer

PURPOSE: The activating mutation AKT1(E17K) occurs in ~7% of ER+ metastatic breast cancer (MBC). We report, from a multipart, first-in-human, Phase I study (NCT01226316), tolerability and activity of capivasertib, an oral AKT inhibitor, as monotherapy or combined with fulvestrant in expansion cohort...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Clin Cancer Res
Main Authors: Smyth, Lillian M., Tamura, Kenji, Oliveira, Mafalda, Ciruelos, Eva, Mayer, Ingrid A., Sablin, Marie-Paule, Biganzoli, Laura, Ambrose, Helen, Ashton, Jack, Barnicle, Alan, Cashell, Des, Corcoran, Claire, de Bruin, Elza C., Foxley, Andrew, Hauser, Joana, Lindemann, Justin P.O., Maudsley, Rhiannon, McEwen, Robert, Moschetta, Michele, Pass, Martin, Rowlands, Vicky, Schiavon, Gaia, Banerji, Udai, Scaltriti, Maurizio, Taylor, Barry S., Chandarlapaty, Sarat, Baselga, José, Hyman, David M.
Format: Artigo
Sprog:Inglês
Udgivet: 2020
Fag:
Article
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7415507/
https://ncbi.nlm.nih.gov/pubmed/32312891
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-19-3953
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker